REAGAN-UDALL FOUNDATION FOR THE FDA

Online Controlled Substances Virtual Summit 2025

Thursday, September 11, 2025

12:30-3:30pm (*eastern*) | Zoom Virtual Platform

Speaker Biographies

Saleem Alhabash, PhD
Professor & Associate Chair, Department of Advertising and Public Relations
Associate Direct of Research, Center for Anti-Counterfeiting and Product Protection
Michigan State University

Dr. Saleem Alhabash is Professor of Advertising and Public Relations at Michigan State University's Department of Advertising and Public Relations, where he also serves as Associate Director of Research at the Center for Anti-Counterfeiting and Product Protection (A-CAPP). His research focuses on the processes and effects of new and social media within the context of persuasion. More specifically, his research investigates the cognitive and emotional responses, and psychological effects associated with using new and social media. His research is geared toward understanding how new communication technologies can be used as persuasive tools, most recently in relation to marketing of alcohol, digital aggression across the lifespan, and consumer behavior of buying counterfeits online. He also studies how new and social media can facilitate cross-cultural and international communication, with emphasis on changing attitudes and stereotypes of foreign nations. At the A-CAPP Center, Dr. Alhabash leads the Center's research portfolio, including conducting original research and facilitating research among interdisciplinary and multi-disciplinary teams from around the world. Specifically, he led a 17-country focused on why and how consumers buy counterfeit products online and is currently leading an eight-country study on the purchase behavior of medications online, including those that are substandard, falsified, and counterfeit. He has also been leading industry-wide research in the field of intellectual property protection, including a study of IP professionals' perceptions of AI threats and benefits, an IP job task analysis, and assessment of the effectiveness of anti-counterfeit campaigns. In 2014, he was named the inaugural recipient of the American Academy of Advertising's Mary Alice Shaver Promising Professor Award, and he was named an Institute for Diverse Leadership Fellow at the Association for Education in Journalism and Mass Communication (AEJMC). His research won best article, top paper, and top poster awards at national and international conferences. He's an associate editor for Journal of Advertising. Dr. Alhabash received his PhD from the University of Missouri School of Journalism. Pre-academia, he worked in a youth nonprofit organization focusing on media and well-being.

Michael Carson
Senior Director, Regulatory Policy
eBay

Mike joined eBay in 2005 and is part of the Regulatory Policy team. In this role, Mike is responsible for developing and implementing policies to effectively manage eBay's regulatory, industry, and brand risks and working with global regulators, law enforcement, NGOs and private industry to protect the safety and security of the Marketplace. Mike also spent five years at PayPal heading their North America Brand Risk Management Group. Prior to joining eBay and PayPal in 2005, Mike worked in the government relations field for an issues management group focusing on technology and privacy matters. In addition, Mike also spent three years in the public sector serving as Staff Director for the Senate Minority Leader's Office in the Massachusetts State House. Mike is a Boston College graduate with a BA in Political Science. Mike currently lives in San Diego with his wife Ellen and their daughter Siena.

Sangeeta Vaswani Chatterjee, PharmD
Acting Director, Office of Drug Security, Integrity, and Response, Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Dr. Sangeeta V. Chatterjee currently serves as the Acting Director of the Office of Drug Security, Integrity, and Response within the Center for Drug Evaluation and Research's Office of Compliance at the U.S. Food and Drug Administration (FDA). In this capacity, she provides executive leadership for a wide range of efforts to safeguard the U.S. drug supply chain. Her experience spans innovative compliance initiatives, risk mitigation, and cross-sector engagement to address major public health threats, including substandard and falsified medicines and the opioid crisis, on a global scale.

She brings extensive regulatory and compliance expertise from across the Agency. At the Center for Tobacco Products, she championed novel enforcement strategies to address violative tobacco product promotion. In the Office of Prescription Drug Promotion, she directed compliance actions and policy development for prescription drug advertising. Before joining FDA, she held oncology regulatory strategy and promotion compliance roles in the pharmaceutical industry.

Dr. Chatterjee earned her Doctor of Pharmacy Degree from the University of the Sciences in Philadelphia. She completed the Visiting Scientist Fellowship in Regulatory Affairs at Eli Lilly and Company and served as an adjunct professor at Butler University. She is also an alumna of the Executive Leadership Program of Northwestern University's Kellogg School of Management. Her outstanding work to protect public health has earned her prestigious accolades, including FDA Commissioner's Special Citations and the Journal of Medical Regulation Award for Excellence in Medical Writing.

Jim Crotty, JD, MA
Law Enforcement Outreach Manager
Meta

Jim Crotty is a global thought leader and subject matter expert in law enforcement, intelligence, transnational organized crime, and drug policy. Mr. Crotty spent over 12 years with the U.S. Drug Enforcement Administration (DEA), serving in strategic, tactical, and operational positions domestically and overseas. In his final assignment with DEA, Mr. Crotty was selected to be the Deputy Chief of Staff and Executive Assistant to the Administrator.

Mr. Crotty is currently a Law Enforcement Outreach Manager at Meta Platforms, Inc., where he is responsible for developing and maintaining strategic relationships with law enforcement across North America to help combat criminal activity. Mr. Crotty joined Meta after a year and a half at the DC Metropolitan Police Department (MPD), where he led the Investigative Support Section, a real-time intelligence center focused on major crimes taking place in the District of Columbia. Mr. Crotty joined MPD in March 2023 after two years at The Cohen Group, a strategic advisory firm founded by former Secretary of Defense William Cohen. While at The Cohen Group, Mr. Crotty led multiple client teams across the defense, cybersecurity, healthcare, energy, and national security sectors.

Mr. Crotty serves as an Adjunct Professor at American University's School of Public Affairs where he teaches courses on Organized Crime and Drugs, Crime, and Public Policy. He sits on the Advisory Board of United Against Fentanyl, is a Non-Resident Senior Fellow at the University of South Florida's Global and National Security Institute (GSI), and an active member of the Global Initiative Against Transnational Organized Crime (GI-TOC) Network of Experts. He is a former Senior Fellow at the Center for Advanced Defense Studies (C4ADS) and Presidential Management Fellow.

Mr. Crotty holds a JD from the University of Alabama School of Law, MA in Political Science from Boston College, and BA in Political Science from Auburn University, *summa cum laude*.

Stephen Dufresne
Manager, Safety Operations Outreach
Snap Inc.

Stephen Dufresne is a Safety Operations Outreach Manager at Snap Inc. with over fifteen years of experience in online safety and digital privacy and has held multiple leadership roles across Snap's Safety Operations teams.

Jake Ellis
Senior Operations Manager, Office of Criminal Investigations
U.S. Food and Drug Administration

Special Agent Jacob (Jake) Ellis started his federal law enforcement career in 2003 as an Inspector with Customs and Border Protection in Miami, FL and transferred to the US Secret Service as a Special Agent in 2005. While employed at the US Secret Service, he conducted investigations related to identity theft, credit card fraud and money laundering. Jake was also assigned to US Secret Service Headquarters in the Asset Forfeiture Division and various assignments in the Office of Protective Operations. Jake joined FDA-OCI in 2015 in the Metro Washington Field Office and was soon assigned to the Cybercrime Investigations Unit. While in this assignment he conducted investigations into counterfeit drug distribution on the clear and dark web, and financial investigations into cryptocurrency. In 2022, Jake was promoted to Senior Operations Manager for the Cybercrime Investigations Unit, managing cyber intelligence and liaison. In 2025, Jake was assigned as the National Training Coordinator for FDA-OCI.

Nathaniel (Nate) Feltner, JD
Principal Corporate Counsel
Microsoft

Nate has been with Microsoft for 10 years where he currently supports the AI and web engineering teams working on the Bing Search and CoPilot services. Prior to joining Microsoft, Nate practiced law in both the public sector and in private practice. Nate earned his JD from Seattle University School of Law and his BA from the University of Washington.

Jennifer Frink
Family Representative

Jen Frink joined the speaking panel to tell the story of losing her 21-year-old son Tasman to an accidental overdose from drugs purchased on the dark web in 2024. By sharing her family's story, she hopes to prevent other deaths and raise awareness. Professionally, Jen works in Global Supply Chain Finance for Nike, Inc. and has over 20 years' experience working for both a Fortune 100 company and start-ups. She has a long history working with youth and is a past Board Member of Children's Healing Art Project. More information on Tasman can be found here.

Grace Graham, MPP
Deputy Commissioner for Policy, Legislation, and International Affairs
U.S. Food and Drug Administration

Grace Graham is the Deputy Commissioner for Policy, Legislation, and International Affairs. In this role, she leads the Office of Policy, Legislation, and International Affairs (OPLIA), which serves as the FDA's focal point for engagement with the U.S. Congress, the Administration, global counterparts and partners, and state, local, territorial, and tribal policymakers.

Immediately before coming to the FDA, Grace served as Chief Health Counsel for the Energy and Commerce Committee (E&C) in the U.S. House of Representatives, where she worked on the 2022 User Fee Reauthorization and other health care matters under the scope of the committee. Prior to that, Mrs. Graham served as Health Policy Director for the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP), working on User Fee Legislation, 21st Century Cures laws, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act, and other health care legislation.

Grace has a Master of Public Policy and Health Policy, as well as a Bachelor of Science in Biomedical Engineering from the University of Virginia.

Carrie Harney, JD
Vice President, U.S. Government and Regulatory Affairs
US Pharmacopeia

Carrie Harney is Vice President for US Government and Regulatory Affairs at the United States Pharmacopeia (USP). In her position, she leads the development of USP's public policy initiatives to advance quality in medicines, dietary supplements, food, and healthcare. She also works closely on FDA regulatory issues and leads USP engagement with federal and state regulators. Prior to joining USP, she worked for an innovative biopharmaceutical company, where she developed and implemented strategic policy priorities and represented the company in various trade association working groups. Carrie began her career as a food and drug attorney, providing regulatory advice to companies and trade associations in the pharmaceutical, food, dietary supplement, cosmetic, and tobacco industries. She earned a BA in Biology from St. Mary's College of Maryland and a JD from the University of Maryland School of Law.

John Hertig, PharmD, MS
Founder
Hertig Healthcare Advising, LLC

Dr. Hertig is former faculty and Past-Chair of the Pharmacy Practice Department in the Butler University College of Pharmacy and Health Sciences (Indianapolis, USA). Dr. Hertig lectures around the world and publishes on a variety of patient safety, leadership, administration, and health policy topics. He serves as an Editor-in-Chief for the Journal of Medicine Access, and his extensive research program is designed to enhance the safety of the medication use process, while using evidence to inform patient advocacy efforts.

Dr. Hertig is a Member of the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee. He holds other national and international appointments, including with the International Pharmaceutical Federation, where he is Treasurer for the Hospital Pharmacy Section, and as Past-President of the Board of Directors for the Alliance for Safe Online Pharmacies – Global (ASOP), where he leads efforts to reduce the patient safety impact of illegal and counterfeit online drug distribution worldwide.

He was awarded the ASOP Global Patient Safety Champion Award in 2018. Dr. Hertig received his Bachelor of Science in Pharmaceutical Sciences and Doctor of Pharmacy degrees from Purdue University (USA). He completed a PGY1 pharmacy practice and PGY2 health-system pharmacy administration residency at The Ohio State University Medical Center while also obtaining a Master's degree in Health-System Pharmacy Administration from The Ohio State University (USA).

He is a Certified Professional in Patient Safety (CPPS), a Fellow of the American Society of Health System Pharmacists (FASHP), and a Fellow of the International Pharmaceutical Federation (FFIP)

Angie Hoth, PharmD, MPH
Research Consultant
Reagan-Udall Foundation for the FDA

Angie Hoth is currently a research consultant with the Reagan-Udall Foundation for the Food and Drug Administration, working on projects in the Substance Use Disorder and Regulatory Science Accelerator programs. Dr. Hoth has over 30 years of experience as a clinical pharmacy specialist, working in primary care, geriatrics, mental health, and HIV prevention. Her passion is in the implementation and evaluation of novel clinical collaborative services. She was the program lead for a five-year CDC-funded PS18-1802 Component B Demonstration Project: Tele-Medical Pre-Exposure Prophylaxis (PrEP) Delivery in a Rural State which established the statewide Iowa TelePrEP service. Prior to that she was employed by the Iowa City VA Medical Center for fifteen years and worked on a wide variety of projects in health services

research, program evaluation, and in the tech sector. Dr. Hoth received her B.S. Pharmacy degree at the University of Iowa College of Pharmacy, her Pharm.D. at the University of Texas Health Science Center in San Antonio, TX, completed a specialty residency in primary care and geriatrics at the Audie L. Murphy VA in San Antonio, TX, and received her MPH at the University of California, Berkeley. She began her pharmacy career as an assistant professor at the University of Kentucky College of Pharmacy.

Vladmir Kostic
Data Analyst
United Nations International Narcotics Control Board

Vladimir Kostic is a Data Analyst with the United Nations International Narcotics Control Board (INCB), where he leads a team building data-driven tools to help law-enforcement agencies counter trafficking in synthetic drugs, new psychoactive substances (NPS), and related chemicals. He designed and implemented GRIDS Intelligence and the GRIDS Targeting Assist (GTA) machine-learning algorithm, enabling data-led risk profiling and operational targeting. He also manages SNOOP, INCB's online monitoring platform that detects open-web advertisements for controlled and dangerous substances. His work turns large, multi-source datasets into actionable leads for police, customs, and regulators while protecting legitimate supply chains from diversion and misuse.

Laila Sofia Mouawad, MS
Technical Officer, International Cooperation Unit
Brazilian Regulatory Health Agency (ANVISA)
Vice-chair, WHO Member State Mechanism on Substandard and Falsified Medical Products

Laila Sofia Mouawad, Technical Officer at the International Cooperation Unit, Brazilian Health Regulatory Agency (ANVISA). Degree in Biology from the Federal University of Paraná; Graduate in Regulation and Health Surveillance from the University of São Paulo; Graduate in International Health from the Fiocruz Foundation; MSc in Political Sciences from the University of Bristol. ANVISA staff member since 2005. Vice-chair of the WHO Member State Mechanism on Substandard and Falsified Medical Products since 2020.

Marta Sokolowska, PhD
Deputy Center Director for Substance Use and Behavioral Health
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Dr. Marta Sokolowska is the Deputy Center Director for Substance Use and Behavioral Health in FDA's Center for Drug Evaluation and Research (CDER). She serves as the center's executive-level leader responsible for advancing FDA's public health response to the non-medical use of substances with abuse potential. With expertise in science-based assessment and management of drug abuse risks, Dr. Sokolowska advises senior FDA officials on shaping scientific and policy interventions and executing strategies pertaining to the use of controlled substances and behavioral health programs. Dr. Sokolowska joined CDER in 2018 as Associate Director for Controlled Substances in the Office of the Center Director. In 2020, she began leading the Controlled Substances Program (CSP), which comprises the Controlled Substance Staff (CSS) and the Controlled Substances Initiatives (CSI) group. CSS provides consultation throughout FDA on evaluation of abuse potential of drugs and advises on all matters related to domestic and international drug scheduling. The strategy group pursues activities and policies to identify, mitigate, and manage emerging issues with controlled substances to minimize risks associated with problematic use while enabling appropriate access to these products for medical use. Dr. Sokolowska is a recognized expert in drug abuse liability and scheduling strategies. She has facilitated numerous initiatives to improve public health by advancing the science of assessing drug abuse liability. Prior to joining FDA, Dr. Sokolowska held senior clinical and medical leadership roles in the pharmaceutical industry. She earned her doctoral degree in psychology from McMaster University in Canada.

Ed Ternan
President & Co-founder
Song for Charlie

Ed Ternan is a husband, father and businessman. In May 2020, he lost his 22-year-old son Charlie, who was poisoned by a counterfeit prescription pill. Since that time, Ed and his wife Mary have dedicated themselves to informing young people about the new risks of self-medication and recreational drug use in the age of synthetic drugs like fentanyl.

The Ternans have formed a nonprofit charity called Song for Charlie, where they create and distribute fentanyl awareness and drug education materials online, on campus and via social media. Their programs are designed to provide useful, fact-based resources to young people, families and educators, with the goal of reducing drug use and encouraging healthier strategies for managing stress.

Moderator

Susan C. Winckler, RPh, Esq.
Chief Executive Officer
Reagan-Udall Foundation for the FDA

Susan C. Winckler is CEO of the Reagan-Udall Foundation for the FDA (Foundation). The Foundation is the non-profit organization created by Congress to advance the mission of the FDA. Prior to accepting the Foundation post in May of 2020, Ms. Winckler served as President of Leavitt Partners Solutions. As President and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advised corporate executives on policy and business matters. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, industry leaders, and consumers with a neutral forum to address domestic and global issues. As FDA Chief of Staff from 2007-2009, Ms. Winckler managed the Commissioner's office; served as his/her senior staff adviser; analyzed policies; and represented FDA before myriad government and external stakeholders. She simultaneously led FDA's Offices of Legislation, External Relations, Public Affairs, and Executive Secretariat. As APhA Vice President Policy/Communications and Staff Counsel, she served as the association's lead spokesperson and senior liaison to Congress, the executive branch, state associations, and allied groups. Ms. Winckler earned a bachelor's degree from the University of Iowa College of Pharmacy and her juris doctorate magna cum laude from Georgetown University Law Center. She served as an elected member United States Pharmacopeial Convention (USP) Board of Trustees (2015-2020, 2020-2025) and Chair of that Board from 2019 to mid-2025. She is an APhA Fellow, a member of the Purgo Scientific, LLC board, and a member of the Virginia Commonwealth University School of Pharmacy National Advisory Council.